Abstract
Two distinct helper T (TH) subsets, TH1 and TH17, mediate tissue damage and inflammation in animal models of various immune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases and allergic skin disorders. These experimental findings, and the implication of these TH subsets in human diseases, suggest the need for pharmacological measures to manipulate these TH subsets. Here we show that prostaglandin E2 (PGE2) acting on its receptor EP4 on T cells and dendritic cells not only facilitates TH1 cell differentiation but also amplifies interleukin-23–mediated TH17 cell expansion in vitro. Administration of an EP4-selective antagonist in vivo decreases accumulation of both TH1 and TH17 cells in regional lymph nodes and suppresses the disease progression in mice subjected to experimental autoimmune encephalomyelitis or contact hypersensitivity. Thus, PGE2-EP4 signaling promotes immune inflammation through TH1 differentiation and TH17 expansion, and EP4 antagonism may be therapeutically useful for various immune diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Steinman, L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage. Nat. Med. 13, 139–145 (2007).
Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V.K. IL-17 and TH17 cells. Annu. Rev. Immunol. 27, 485–517 (2009).
Steinman, L. A rush to judgment on TH17. J. Exp. Med. 205, 1517–1522 (2008).
Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521–533 (2003).
Lowes, M.A., Bowcock, A.M. & Krueger, J.G. Pathogenesis and therapy of psoriasis. Nature 445, 866–873 (2007).
Lock, C. et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500–508 (2002).
Tzartos, J.S. et al. Interleukin-17 produciton in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146–155 (2008).
Moldovan, I.R. et al. Interferon γ responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J. Neuroimmunol. 141, 132–140 (2003).
Fassbender, K. et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 51, 753–758 (1998).
Ziolkowska, M. et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A–sensitive mechanism. J. Immunol. 164, 2832–2838 (2000).
Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65–70 (2003).
Annunziato, F. et al. Phenotypic and functional feature of human TH17 cells. J. Exp. Med. 204, 1849–1861 (2007).
Lowes, M.A. et al. Psoriasis vulgaris lesions contain discrete populations of TH1 and TH17 T cells. J. Invest. Dermatol. 128, 1207–1211 (2008).
Duerr, R.H. et al. A genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
Xavier, R.J. & Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427–434 (2007).
Capon, F. et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122, 201–206 (2007).
Mannon, P.J. et al. Anti–interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069–2079 (2004).
Krueger, G.G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
Narumiya, S. Physiology and pathophysiology of prostanoid receptors. Proc. Japan Acad. Ser. B. 83, 296–319 (2007).
Goodwin, J.S. & Ceuppens, J. Regulation of the immune response by prostaglandins. J. Clin. Immunol. 3, 295–315 (1983).
Hasler, F., Bluestein, H.G., Zvaifler, N.J. & Epstein, L.B. Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E. J. Immunol. 131, 768–772 (1983).
Betz, M. & Fox, B.S. Prostaglandin E2 inhibits production of TH1 lymphokines but not of Th2 lymphokines. J. Immunol. 146, 108–113 (1991).
Gold, K.N., Weyand, C.M. & Goronzy, J.J. Modulation of helper T cell function by prostaglandins. Arthritis Rheum. 37, 925–933 (1994).
Hilkens, C.M. et al. Differential modulation of T helper type 1 (TH1) and T helper type 2 (TH2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur. J. Immunol. 25, 59–63 (1995).
Harris, S.G., Padilla, J., Koumas, L., Ray, D. & Phipps, R.P. Prostaglandins as modulators of immunity. Trends Immunol. 23, 144–150 (2002).
Sugimoto, Y. & Narumiya, S. Prostaglandin E receptors. J. Biol. Chem. 282, 11613–11617 (2007).
Nataraj, C. et al. Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse. J. Clin. Invest. 108, 1229–1235 (2001).
Mustelin, T. & Tasken, K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem. J. 371, 15–27 (2003).
Chemnitz, J.M. et al. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res. 66, 1114–1122 (2006).
Suzawa, T. et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141, 1554–1559 (2000).
Narumiya, S. & FiztGerald, G.A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108, 25–30 (2001).
Kabashima, K. et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883–893 (2002).
Segi, E. et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4–deficient mice. Biochem. Biophys. Res. Commun. 246, 7–12 (1998).
Hizaki, H. et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2 . Proc. Natl. Acad. Sci. USA 96, 10501–10506 (1999).
Christensen, A.E. et al. cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J. Biol. Chem. 278, 35394–35402 (2003).
Murray, A.J. Pharmacological PKA inhibition: all may not be what it seems. Sci. Signal. 1, re4 (2008).
Carpenter, C.L. & Cantley, L.C. Phosphoinositide kinases. Curr. Opin. Cell Biol. 8, 153–158 (1996).
Buchanan, F.G. et al. Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl. Acad. Sci. USA 103, 1492–1497 (2006).
Regan, J.W. EP2 and EP4 prostanoid receptor signaling. Life Sci. 74, 143–153 (2003).
Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317–330 (2003).
Langrish, C.L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005).
Lee, Y.K. et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92–107 (2009).
Nurieva, R., Yang, X.O., Chung, Y. & Dong, C. Cutting edge: In vitro generated TH17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J. Immunol. 182, 2565–2568 (2009).
Nakae, S. et al. Antigen-specific T cell sensitization is impaired in IL-17–deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17, 375–387 (2002).
Serada, S. et al. IL-6 blockade inhibits the induction of myelin antigen–specific TH17 cells and TH1 cells in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105, 9041–9046 (2008).
Kabashima, K. et al. Prostaglandin E2–EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat. Med. 9, 744–749 (2003).
Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).
Sheibanie, A.F. et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis. J. Immunol. 178, 8138–8147 (2007).
Khayrullina, T., Yen, J.H., Jing, H. & Ganea, D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of TH17 cells. J. Immunol. 181, 721–735 (2008).
Nagamachi, M. et al. Facilitation of TH1-mediated immune response by prostaglandin E receptor EP1. J. Exp. Med. 204, 2865–2874 (2007).
Bos, J.L. Epac proteins: multi-purpose cAMP targets. Trends Biochem. Sci. 31, 680–686 (2006).
Libioulle, C. et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 3, e58 (2007).
Neurath, M.F. IL-23: a master regulator in Crohn disease. Nat. Med. 13, 26–28 (2007).
Hervé, M. et al. Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion. Eur. J. Immunol. 33, 2764–2772 (2003).
Kabashima, K. et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol. 4, 694–701 (2003).
Chizzolini, C. et al. Prostaglandin E2 synergistically with interleukin-23 favors human TH17 expansion. Blood 112, 3696–3703 (2008).
Boniface, K. et al. Prostaglandin E2 regulates TH17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206, 535–548 (2009).
Acknowledgements
We thank Ono Pharmaceutical Company for supplying EP agonists and EP4 antagonist. We also thank Q. Chen and M. Lamphier for information about their experiments, M. Hikida for cell sorting, T. Fujiwara for animal care and K. Nonomura and T. Arai for assistance. This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by a grant from the National Institute of Biomedical Innovation of Japan.
Author information
Authors and Affiliations
Contributions
D.S., Y.S. and S.N. designed and discussed experiments; C.Y., D.S. and T.M. performed experiments on TH1 and TH17 differentiation and expansion; C.Y. and D.S. performed experiments on CHS; Y.E., Y.L. and D.S. performed experiments on EAE; C.Y., K.K. and Y.S. performed experiments on signaling; C.Y., D.S. and S.N. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
This study was supported in part by a collaborative grant to Kyoto University from Ono Pharmaceuticals Company Ltd., which also partially funded the colonies of transgenic mice and provided EP agonists and an EP4 antagonist used in the study.
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–5 and Supplementary Methods (PDF 149 kb)
Rights and permissions
About this article
Cite this article
Yao, C., Sakata, D., Esaki, Y. et al. Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med 15, 633–640 (2009). https://doi.org/10.1038/nm.1968
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.1968
This article is cited by
-
Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: fueling or dampening disease progression?
Journal of Neuroinflammation (2024)
-
Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension
Respiratory Research (2023)
-
The role of non-steroidal anti-inflammatory drugs as adjuncts to periodontal treatment and in periodontal regeneration
Journal of Translational Medicine (2023)
-
Pro- and anti-inflammatory bioactive lipids imbalance contributes to the pathobiology of autoimmune diseases
European Journal of Clinical Nutrition (2023)
-
Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?
Current Pulmonology Reports (2023)